97 related articles for article (PubMed ID: 38570462)
1. Correction: Satam et al. Next-Generation Sequencing Technology: Current Trends and Advancements.
Satam H; Joshi K; Mangrolia U; Waghoo S; Zaidi G; Rawool S; Thakare RP; Banday S; Mishra AK; Das G; Malonia SK
Biology (Basel); 2024 Apr; 13(5):. PubMed ID: 38785841
[TBL] [Abstract][Full Text] [Related]
2. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.
Yang H; Zhou X; Fu D; Le C; Wang J; Zhou Q; Liu X; Yuan Y; Ding K; Xiao Q
Cancer Commun (Lond); 2023 Jan; 43(1):42-74. PubMed ID: 36316602
[TBL] [Abstract][Full Text] [Related]
3. Probing RAS Function Using Monobody and NanoBiT Technologies.
Whaby M; Nair RS; O'Bryan JP
Methods Mol Biol; 2024; 2797():211-225. PubMed ID: 38570462
[TBL] [Abstract][Full Text] [Related]
4. Probing RAS Function with Monobodies.
Khan I; O'Bryan JP
Methods Mol Biol; 2021; 2262():281-302. PubMed ID: 33977484
[TBL] [Abstract][Full Text] [Related]
5. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
6. Microvesicles as mediators of intercellular communication in cancer.
Antonyak MA; Cerione RA
Methods Mol Biol; 2014; 1165():147-73. PubMed ID: 24839024
[TBL] [Abstract][Full Text] [Related]
7. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract][Full Text] [Related]
8. Patient-Derived In Vitro and In Vivo Models of Cancer.
Claridge SE; Cavallo JA; Hopkins BD
Adv Exp Med Biol; 2022; 1361():215-233. PubMed ID: 35230691
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the α4-α5 allosteric lobe of RAS do not significantly impair RAS signaling or self-association.
Whaby M; Wallon L; Mazzei M; Khan I; Teng KW; Koide S; O'Bryan JP
J Biol Chem; 2022 Dec; 298(12):102661. PubMed ID: 36334633
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket.
Wallon L; Khan I; Teng KW; Koide A; Zuberi M; Li J; Ketavarapu G; Traaseth NJ; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2204481119. PubMed ID: 36252024
[TBL] [Abstract][Full Text] [Related]
11. Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants.
Khan I; Koide A; Zuberi M; Ketavarapu G; Denbaum E; Teng KW; Rhett JM; Spencer-Smith R; Hobbs GA; Camp ER; Koide S; O'Bryan JP
Cell Rep; 2022 Feb; 38(6):110322. PubMed ID: 35139380
[TBL] [Abstract][Full Text] [Related]
12. Targeting the "undruggable" RAS with biologics.
Whaby M; Khan I; O'Bryan JP
Adv Cancer Res; 2022; 153():237-266. PubMed ID: 35101232
[TBL] [Abstract][Full Text] [Related]
13. D154Q Mutation does not Alter KRAS Dimerization.
Grozavu I; Stuart S; Lyakisheva A; Yao Z; Pathmanathan S; Ohh M; Stagljar I
J Mol Biol; 2022 Jan; 434(2):167392. PubMed ID: 34896362
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic KRAS G12D mutation promotes dimerization through a second, phosphatidylserine-dependent interface: a model for KRAS oligomerization.
Lee KY; Enomoto M; Gebregiworgis T; Gasmi-Seabrook GMC; Ikura M; Marshall CB
Chem Sci; 2021 Oct; 12(38):12827-12837. PubMed ID: 34703570
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
